Tags : Co-develop

Pharma

Gilead Signs a Ten Years Agreement with Arcus to Co-Develop

Shots: Arcus to receive $375M including $175M up front & $200M as equity investment at a price of $33.54/ share with a premium of 35% and is eligible to receive $1.225B as in opt-in and milestones concerning its current clinical product candidates.  Gilead will support the ongoing research and development by paying $400M during the […]Read More

Biotech COVID-19

Lilly and Junshi Collaborate to Co-Develop Antibody Therapies for the

Shots: Lilly will get an exclusive license to perform clinical development, manufacturing and distribution of products outside of China while Junshi will maintain all rights in Greater China The collaboration will accelerate the clinical development of Junshi’s Ab therapies against COVID-19 globally. Both the companies have submitted the IND application and anticipate the initiation of […]Read More

Biotech COVID-19

Pfizer and BioNTech Collaborate to Co-Develop BNT162 Against COVID-19

Shots: The companies collaborate to accelerate the development of BioNTech’s BNT162, which is anticipated to enter clinical studies by the end of Apr’2020. The alliance will leverage the expertise and resources of both companies to co-develop mRNA-based vaccine candidate globally (Ex- China) The collaboration follows 2018 agreement signed b/w the companies to develop mRNA-based vaccines […]Read More

Biotech COVID-19

AbCellera and Eli Lilly Collaborate to Co-develop Antibody Therapies Targeting

Shots: The alliance will leverage AbCellera’s rapid pandemic response platform, developed under the DARPA P3 program with Eli Lilly’s development & manufacturing capabilities. The companies will equally share the initial development cost while Lilly will be solely responsible for further development, manufacturing & distribution activities The companies have identified ~500+ unique Ab isolated from one […]Read More

Biotech COVID-19

Codagenix Collaborates with Serum Institute of India to Co-Develop a

Shots: Codagenix will utilize its deoptimization technology for viral deoptimization, designed several nCoV vaccine candidate genomes, will grow and conduct in-vivo tests of vaccine viruses prior to testing in clinical studies The Serum Institute of India will scale up the manufacturing of vaccines to ensure its availability to meet the public needs. The companies are […]Read More

Biotech

Astellas and Adaptimmune Signs Co-Exclusive Agreement for Universal Donor Cell

Shots: Adaptimmune to receive $50M up front, ~73.75M development milestones/ target (if product co-developed & co-commercialized by both companies) and $147.5M as milestones/product & $110M as commercial milestone if products developed by Astellas. Additionally, Adaptimmune to receive up to $7.5M/ yr. as research funding and royalties on net sales of the products Astellas to receive […]Read More

Biosimilars

Gene Techno Science Signs an Agreement with Kishi Kasei to

Shots: GTS and Kishi Kasei will jointly develop biosimilar of Aflibercept and will form a manufacturing process for the drug substance utilizing high-yield protein-producing cell lines, which were jointly developed by GTS and Fuso Pharmaceutical The collaboration focusses to secure a future revenue base via commercialization of biosimilar of Aflibercept and to gain market share […]Read More